X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ALKEM LABORATORIES - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ALKEM LABORATORIES CIPLA/
ALKEM LABORATORIES
 
P/E (TTM) x 43.5 - - View Chart
P/BV x 3.6 6.0 60.1% View Chart
Dividend Yield % 0.4 0.7 49.3%  

Financials

 CIPLA   ALKEM LABORATORIES
EQUITY SHARE DATA
    CIPLA
Mar-17
ALKEM LABORATORIES
Mar-16
CIPLA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6221,589 39.1%   
Low Rs4581,232 37.2%   
Sales per share (Unadj.) Rs181.9417.5 43.6%  
Earnings per share (Unadj.) Rs12.956.3 22.9%  
Cash flow per share (Unadj.) Rs29.364.7 45.3%  
Dividends per share (Unadj.) Rs2.0012.70 15.7%  
Dividend yield (eoy) %0.40.9 41.1%  
Book value per share (Unadj.) Rs155.7292.9 53.1%  
Shares outstanding (eoy) m804.51119.57 672.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.4 87.9%   
Avg P/E ratio x42.025.1 167.5%  
P/CF ratio (eoy) x18.421.8 84.5%  
Price / Book Value ratio x3.54.8 72.0%  
Dividend payout %15.522.6 68.9%   
Avg Mkt Cap Rs m434,516168,653 257.6%   
No. of employees `00023.0NA-   
Total wages/salary Rs m26,3389,171 287.2%   
Avg. sales/employee Rs Th6,349.1NM-  
Avg. wages/employee Rs Th1,143.0NM-  
Avg. net profit/employee Rs Th449.3NM-  
INCOME DATA
Net Sales Rs m146,30249,915 293.1%  
Other income Rs m2,2871,645 139.0%   
Total revenues Rs m148,58951,561 288.2%   
Gross profit Rs m24,7588,482 291.9%  
Depreciation Rs m13,2291,006 1,315.3%   
Interest Rs m1,594671 237.7%   
Profit before tax Rs m12,2228,451 144.6%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7981,606 111.9%   
Profit after tax Rs m10,3546,731 153.8%  
Gross profit margin %16.917.0 99.6%  
Effective tax rate %14.719.0 77.4%   
Net profit margin %7.113.5 52.5%  
BALANCE SHEET DATA
Current assets Rs m87,37027,062 322.9%   
Current liabilities Rs m33,08115,324 215.9%   
Net working cap to sales %37.123.5 157.8%  
Current ratio x2.61.8 149.6%  
Inventory Days Days8767 130.8%  
Debtors Days Days6241 150.9%  
Net fixed assets Rs m111,56712,610 884.8%   
Share capital Rs m1,609239 672.9%   
"Free" reserves Rs m123,64534,490 358.5%   
Net worth Rs m125,25435,027 357.6%   
Long term debt Rs m36,4541,212 3,008.7%   
Total assets Rs m209,53254,387 385.3%  
Interest coverage x8.713.6 63.7%   
Debt to equity ratio x0.30 841.4%  
Sales to assets ratio x0.70.9 76.1%   
Return on assets %5.713.6 41.9%  
Return on equity %8.319.2 43.0%  
Return on capital %8.524.9 34.2%  
Exports to sales %34.212.9 264.3%   
Imports to sales %8.33.1 270.3%   
Exports (fob) Rs m50,0506,461 774.6%   
Imports (cif) Rs m12,2031,540 792.2%   
Fx inflow Rs m51,0666,563 778.1%   
Fx outflow Rs m17,6783,012 587.0%   
Net fx Rs m33,3883,552 940.1%   
CASH FLOW
From Operations Rs m23,8247,259 328.2%  
From Investments Rs m-13,1271,864 -704.1%  
From Financial Activity Rs m-13,239-9,273 142.8%  
Net Cashflow Rs m-2,478-150 1,652.0%  

Share Holding

Indian Promoters % 16.0 66.9 23.9%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 33.1 36.9%  
FIIs % 23.7 0.0 -  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 0.0 -  
Shareholders   161,166 68,381 235.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   DR. REDDYS LAB  PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 22, 2017 03:36 PM

TRACK CIPLA

CIPLA - JUBILANT LIFE SCIENCES COMPARISON

COMPARE CIPLA WITH

MARKET STATS